Wegovy for After Bariatric Surgery: Evidence, Eligibility

Wegovy is not FDA approved for weight regain after bariatric surgery. It is approved for weight loss, heart risk and MASH liver disease. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.

Active ingredient: semaglutide
How it is taken: weekly injection or daily tablet
Approved for: Weight loss, heart risk and MASH liver disease
Best result (STEP 1): 14.9% weight loss

Wegovy in brief

Time it remains in your body

Its half-life is about 1 week: after 7 d, half is gone, and after five half-lives (35 d), about 3% remains.

Weight loss in its main trial

In STEP 1 over 68 weeks, people lost 14.9% of body weight, compared with 2.4% on placebo.

Costs over time

Monthly costs in US dollars include the list price and self-pay offers, all taken from the maker's price page.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Wegovy: who qualifies
Who sets the rule	Who qualifies
FDA label	Among adults with heart disease and either obesity or overweight, this medicine lowers the chance of heart attack, stroke, or heart-related death (injection and tablets).
FDA label	With diet and activity, this covers weight loss and keeping the weight off long term. It applies to adults and children aged 12 and older who have obesity, and to adults with a weight-related condition who have overweight.
FDA label	For adults with moderate to advanced scarring from MASH liver disease and no cirrhosis, the injection is a treatment.
FDA label	Tablets are approved for adults to lose weight and lower heart risk.
Medicare GLP-1 Bridge	BMI 35 or higher, no condition needed
Medicare GLP-1 Bridge	CKD 3a+, heart failure, or uncontrolled blood pressure, with a BMI of 30 or more
Medicare GLP-1 Bridge	Prediabetes, a prior stroke or heart attack, or PAD with BMI 27 or higher
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	a diet and activity program lasting 6 months comes first

References: FDA label (DailyMed), medicare.gov 1 2, aetna.com.

Trial results for the period after bariatric surgery

These trials did not enroll only people whose weight returned after bariatric surgery. All participants were adults with obesity or overweight, and none had diabetes.

Wegovy trials for weight regain after bariatric surgery
Trial	Medicine	Who took part	Length	People	Main result	Comparison
STEP 1	Wegovy	Adults with obesity or overweight, without diabetes	68 weeks	1,961	14.9% weight loss	2.4% on placebo
OASIS 4	Wegovy	Adults with obesity or overweight, without diabetes	64 weeks	307	13.6% weight loss	2.4% on placebo

Trial source: STEP 1 (FDA label (DailyMed)).

What is different after bariatric surgery?

Wegovy label details on weight regain after bariatric surgery
What changes	What the label says
Acute Gallbladder Disease	Gallstones and gallbladder inflammation can happen. Report pain in the upper right belly, fever or yellow skin or eyes.
Acute Kidney Injury Due to Volume Depletion	Fluid loss from vomiting or diarrhea may harm the kidneys. Drink fluids and report heavy fluid loss.
Severe Gastrointestinal Adverse Reactions	Stomach and gut side effects are common, and they can be severe. Not recommended for people with severe gastroparesis.
Taken with oral medicines	Your stomach empties more slowly with it, so it can change how other pills are absorbed.

From the FDA labels: FDA label on DailyMed.

FDA label on DailyMed provides the label warnings.

How coverage works after bariatric surgery

Medicare Part D does not cover a GLP-1 used only for weight loss.

Wegovy appears on the Medicare GLP-1 Bridge list at $50 a month. This price applies to people who meet its rules.

When Medicaid covers weight-loss GLP-1s, prior authorization is normally required first.

Sources: humana.com, CMS, KFF.

Other choices after bariatric surgery

GLP-1 medicines for weight regain after bariatric surgery
Medicine	For life after bariatric surgery	How it is taken	Trial result
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Ozempic	Not a listed use	weekly injection	Not listed
Rybelsus	Not a listed use	daily tablet	Not listed
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed